Dear [Name],  
  Our records show that [Name] has not received a vaccination against meningococcal group B disease
(also known as meningitis B).
  Until 2014 there was no vaccine to help protect against meningitis B in the US. Even though your child may have
received the meningitis vaccine (MCV4) that helps protect against groups A, C, Y, and W that cause the disease,
it’s important to be protected against group B in addition to the other 4.1,2 In fact, 50% of meningococcal disease
cases among teens and young adults 17 to 23 years of age in the US are caused by the B bacteria (group B).3
Meningitis B may
lead to death
within 24 hours4
1 in 10 adolescents and
young adults who develop
meningitis B could die from it5
Sharing cups or
utensils, kissing, and other
close-contact activities can
spread the bacteria3
  The good news is that the FDA has approved vaccines for meningitis B, offering you the opportunity to help
protect your child against this uncommon but potentially deadly disease.3,6 Our office carries a multiple-dose
meningitis B vaccine, TRUMENBA, for adolescents and young adults 10 through 25 years of age.
Please call us at [XXX-XXX-XXXX] to discuss vaccination against meningitis B
with TRUMENBA and to schedule an appointment.
Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
Individuals with weakened immune systems may have a reduced immune response
The most common adverse reactions were pain at the injection site, fatigue, headache, muscle pain, and chills
Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B
vaccines interchangeably to complete the vaccination series
Tell your healthcare provider if you are pregnant, or plan to become pregnant
Ask your healthcare provider about the risks and benefits of Trumenba. Only a healthcare provider can decide if
Trumenba is right for you or your child
Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent
invasive disease caused by Neisseria meningitidis group B
Trumenba is approved based upon demonstrated immune response against four group B strains
representative of prevalent strains in the US. The effectiveness of Trumenba against diverse group B
strains has not been confirmed
  Learn More About TRUMENBA  
You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit or call 1-800-822-7967.
Click here for full Prescribing Information.

References: 1. MacNeil JR, Rubin L, Folaranmi T, et al. Centers for Disease Control and Prevention. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1177. 2. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2013;62(RR-2):1-28. 3. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR 2015;64(22):606-607. 4. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 5. Centers for Disease Control and Prevention. Epidemiology of serogroup B meningococcal disease, United States. Advisory Committee on Immunization Practices, October 30, 2014. Centers for Disease Control and Prevention website. Accessed March 26, 2015. 6. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2015.

  PP-TRU-USA-0372 © 2016 Pfizer Inc. All rights reserved. April 2016 Pfizer